Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-06-26
DOI
10.1038/s41598-019-45539-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study
- (2018) Melanie P. Chin et al. AMERICAN JOURNAL OF NEPHROLOGY
- Activation of AQP2 water channels without vasopressin: therapeutic strategies for congenital nephrogenic diabetes insipidus
- (2018) Fumiaki Ando et al. Clinical and Experimental Nephrology
- Tolvaptan for Heart Failure in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
- (2018) Jonathan Sen et al. Heart Lung and Circulation
- Novel treatment strategies for chronic kidney disease: insights from the animal kingdom
- (2018) Peter Stenvinkel et al. Nature Reviews Nephrology
- AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus
- (2018) Fumiaki Ando et al. Nature Communications
- Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression
- (2017) Masahiro Nezu et al. KIDNEY INTERNATIONAL
- Pharmacological chaperone approaches for rescuing GPCR mutants: Current state, challenges, and screening strategies
- (2017) Pieter Beerepoot et al. PHARMACOLOGICAL RESEARCH
- Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors
- (2016) Anju Singh et al. ACS Chemical Biology
- Wnt5a induces renal AQP2 expression by activating calcineurin signalling pathway
- (2016) Fumiaki Ando et al. Nature Communications
- Therapeutic targeting of GSK3β enhances the Nrf2 antioxidant response and confers hepatic cytoprotection in hepatitis C
- (2014) Yongfang Jiang et al. GUT
- Renoprotective Effect of Vasopressin V2 Receptor Antagonist Tolvaptan in Dahl Rats With End-Stage Heart Failure
- (2013) Mayuko Ishikawa et al. International Heart Journal
- Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease
- (2013) V. E. Torres et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy
- (2013) Mohammad A. Aminzadeh et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
- (2013) Dick de Zeeuw et al. NEW ENGLAND JOURNAL OF MEDICINE
- The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease
- (2013) Mohammad A. Aminzadeh et al. XENOBIOTICA
- Signaling Pathways from the Endoplasmic Reticulum and Their Roles in Disease
- (2013) Hisae Kadowaki et al. Genes
- Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling
- (2012) Paul D. Ray et al. CELLULAR SIGNALLING
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
- (2012) Vicente E. Torres et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonclinical Safety Profile of Tolvaptan
- (2011) Akihide Oi et al. CARDIOVASCULAR DRUGS AND THERAPY
- V2 Vasopressin Receptor (V2R) Mutations in Partial Nephrogenic Diabetes Insipidus Highlight Protean Agonism of V2R Antagonists
- (2011) Kazuhiro Takahashi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Role of Intrarenal Angiotensin System Activation, Oxidative Stress, Inflammation, and Impaired Nuclear Factor-Erythroid-2-Related Factor 2 Activity in the Progression of Focal Glomerulosclerosis
- (2011) H. J. Kim et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
- (2011) Pablo E. Pergola et al. NEW ENGLAND JOURNAL OF MEDICINE
- The IRE1α-XBP1 Pathway of the Unfolded Protein Response Is Required for Adipogenesis
- (2009) Haibo Sha et al. Cell Metabolism
- Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats
- (2009) Tadashi Okada et al. Clinical and Experimental Nephrology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started